Company news

InflaRx N.V. news in 2024

InflaRx N.V.'s news releases, calls and decks from 2024, newest first.

View company

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

December 19, 2024

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

November 14, 2024

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

November 7, 2024

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

October 30, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

September 24, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

September 2, 2024

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

August 7, 2024

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

June 23, 2024

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 20, 2024

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

April 29, 2024

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

March 20, 2024

InflaRx Appoints Jan Medina as Head of Investor Relations

February 21, 2024

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

January 24, 2024

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

January 3, 2024

Decks in 2024